Fig. 1: Outcomes of patients with newly diagnosed (ND) and relapsed/refractory (R/R) acute myeloid leukemia with FLT3mut treated with FLT3 inhibitor (FLT3i), venetoclax, and 10-day decitabine (DEC10-VEN). | Blood Cancer Journal

Fig. 1: Outcomes of patients with newly diagnosed (ND) and relapsed/refractory (R/R) acute myeloid leukemia with FLT3mut treated with FLT3 inhibitor (FLT3i), venetoclax, and 10-day decitabine (DEC10-VEN).

From: Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Fig. 1

a Absolute neutrophil count (ANC) recovery to ≥0.5 × 109/L, b platelet count recovery to ≥50 × 109/L, and c overall survival (OS), and d mutational landscape of all patients. NR not reached, MRD measurable residual disease, FCM flow cytometry, multiplex PCR polymerase chain reaction, PCR-based NGS next-generation sequencing.

Back to article page